The treatment with tralokinumab produces sustained responses that offer real benefits to the people living with AD over time.

Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany.

The analysis was of participants from ECZTEND who had previously enrolled in the ECZTRA 1 and 2 phase 3 trials. A total of 347 adult patients using Adtralza for up to four years were included in the analysis. At the end of this period, an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear) (IGA 0/1) was observed in 52.6% of patients. At least a 75% reduction in the Eczema Area and Severity Index (EASI-75) was observed in 84.5% of patients, and an EASI-90 in 64.4%, the study showed.

The safety profile was consistent with earlier analyses, with no new safety signals arising with continued Adtralza use over the four-year treatment period.

“Long-term disease control is a critical need for patients with atopic dermatitis,” says study author Andrew Blauvelt, MD, a dermatologist and Investigator at Oregon Medical Research Center in Portland, in a news release. “These new long-term data demonstrate that treatment with tralokinumab produces sustained responses that offer real benefits to the people living with this debilitating disease over time.”